Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Issue 1 (2nd January 2021)

• Record Type: Journal Article
• Authors: Zackova, Daniela; Klamova, Hana; Belohlavkova, Petra; Stejskal, Lukas; Necasova, Tereza; Semerad, Lukas; Weinbergerova, Barbora; Srbova, Dana; Voglova, Jaroslava; Cicatkova, Petra; Sustkova, Zuzana; Hornak, Tomas; Baranova, Jana; Prochazkova, Jirina; Mayer, Jiri
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 1(2021)
• Page Start: 194
• Page End: 202
• Publication Date: 2021-01-02
• Subjects: Chronic myeloid leukemia -- chronic phase -- imatinib -- dasatinib -- second line -- daily clinical practice; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1827242
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.